APO Research
Talk to an analyst

APO RESEARCH · REPORT

Escitalopram

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Escitalopram Market Analysis and Forecast 2026-2032

27 December 2025210 pages

Choose your research edition.

Industry ResearchEscitalopram Industry Research Report 2026151 pages · $2,950 USDIndustry Growth & TrendsGlobal Escitalopram Industry Growth and Trends Forecast to 2032122 pages · $3,450 USDMarket StructureGlobal Escitalopram Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Escitalopram Market Outlook and Growth Opportunities 2026217 pages · $4,250 USDMarket Analysis & ForecastGlobal Escitalopram Market Analysis and Forecast 2026-2032210 pages · $4,950 USD

Market perspective

The global Escitalopram market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Escitalopram is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Escitalopram is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Escitalopram is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Escitalopram is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Escitalopram include Accord Healthcare (IN), Amneal Pharmaceuticals (US), Apotex (CA), Aurobindo Pharma (IN), Forest Laboratories (US), Hetero Drugs (IN), Hikma Pharmaceuticals (UK), Hunan Dongting Pharmaceutical (CN) and Jewim Pharmaceutical (Shandong), etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Escitalopram, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Escitalopram, also provides the sales of main regions and countries. Of the upcoming market potential for Escitalopram, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Escitalopram sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Escitalopram market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Escitalopram sales, projected growth trends, production technology, application and end-user industry.

Escitalopram Segment by Company

Accord Healthcare (IN)

Amneal Pharmaceuticals (US)

Apotex (CA)

Aurobindo Pharma (IN)

Forest Laboratories (US)

Hetero Drugs (IN)

Hikma Pharmaceuticals (UK)

Hunan Dongting Pharmaceutical (CN)

Jewim Pharmaceutical (Shandong)

Lundbeck (DK)

Lupin (IN)

Macleods Pharmaceuticals (IN)

Silarx Pharmacueticals (US)

TEVA (Israel)

Xidian Pharmaceutical (CN)

Zhejiang Conba Pharmaceutical (CN)

Mylan (US)

Novartis (US)

Sichuan Kelun Pharmaceutical (CN)

Xian Janssen Pharmaceutical (CN)

Zhejiang Huahai Pharmaceutical (CN)

Escitalopram Segment by Type

Tablets

Solution

Escitalopram Segment by Application

Retail Pharmacies

Online Pharmacies

Hospital Pharmacies

Escitalopram Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Escitalopram market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Escitalopram and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Escitalopram.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Escitalopram in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Escitalopram manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Escitalopram sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Escitalopram Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Tablets Major Manufacturers Table 3. Solution Major Manufacturers Table 4. Global Escitalopram Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Retail Pharmacies Major Manufacturers Table 6. Online Pharmacies Major Manufacturers Table 7. Hospital Pharmacies Major Manufacturers Table 8. Escitalopram Industry Trends Table 9. Escitalopram Industry Drivers Table 10. Escitalopram Industry Opportunities and Challenges Table 11. Escitalopram Industry Restraints Table 12. Global Escitalopram Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 13. Global Escitalopram Revenue by Region (2021-2026) & (US$ Million) Table 14. Global Escitalopram Revenue by Region (2027-2032) & (US$ Million) Table 15. Global Escitalopram Revenue Market Share by Region (2021-2026) Table 16. Global Escitalopram Revenue Market Share by Region (2027-2032) Table 17. Global Escitalopram Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (K Units) Table 18. Global Escitalopram Sales by Region (2021-2026) & (K Units) Table 19. Global Escitalopram Sales by Region (2027-2032) & (K Units) Table 20. Global Escitalopram Sales Market Share by Region (2021-2026) Table 21. Global Escitalopram Sales Market Share by Region (2027-2032) Table 22. Global Escitalopram Revenue by Manufacturers (US$ Million) & (2021-2026) Table 23. Global Escitalopram Revenue Market Share by Manufacturers (2021-2026) Table 24. Global Escitalopram Sales by Manufacturers (US$ Million) & (2021-2026) Table 25. Global Escitalopram Sales Market Share by Manufacturers (2021-2026) Table 26. Global Escitalopram Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 27. Global Escitalopram Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 28. Global Escitalopram Key Manufacturers Manufacturing Sites & Headquarters Table 29. Global Escitalopram Manufacturers, Product Type & Application Table 30. Global Escitalopram Manufacturers' Establishment Date Table 31. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 32. Global Escitalopram by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 33. Global Escitalopram Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Escitalopram Revenue by Type (2021-2026) & (US$ Million) Table 35. Global Escitalopram Revenue by Type (2027-2032) & (US$ Million) Table 36. Global Escitalopram Revenue Market Share by Type (2021-2026) Table 37. Global Escitalopram Revenue Market Share by Type (2027-2032) Table 38. Global Escitalopram Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 39. Global Escitalopram Sales by Type (2021-2026) & (K Units) Table 40. Global Escitalopram Sales by Type (2027-2032) & (K Units) Table 41. Global Escitalopram Sales Market Share by Type (2021-2026) Table 42. Global Escitalopram Sales Market Share by Type (2027-2032) Table 43. Global Escitalopram Price by Type (2021-2026) & (US$/Unit) Table 44. Global Escitalopram Price by Type (2027-2032) & (US$/Unit) Table 45. Global Escitalopram Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 46. Global Escitalopram Revenue by Application (2021-2026) & (US$ Million) Table 47. Global Escitalopram Revenue by Application (2027-2032) & (US$ Million) Table 48. Global Escitalopram Revenue Market Share by Application (2021-2026) Table 49. Global Escitalopram Revenue Market Share by Application (2027-2032) Table 50. Global Escitalopram Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 51. Global Escitalopram Sales by Application (2021-2026) & (K Units) Table 52. Global Escitalopram Sales by Application (2027-2032) & (K Units) Table 53. Global Escitalopram Sales Market Share by Application (2021-2026) Table 54. Global Escitalopram Sales Market Share by Application (2027-2032) Table 55. Global Escitalopram Price by Application (2021-2026) & (US$/Unit) Table 56. Global Escitalopram Price by Application (2027-2032) & (US$/Unit) Table 57. Accord Healthcare (IN) Company Information Table 58. Accord Healthcare (IN) Business Overview Table 59. Accord Healthcare (IN) Escitalopram Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 60. Accord Healthcare (IN) Escitalopram Product Portfolio Table 61. Accord Healthcare (IN) Recent Development Table 62. Amneal Pharmaceuticals (US) Company Information Table 63. Amneal Pharmaceuticals (US) Business Overview Table 64. Amneal Pharmaceuticals (US) Escitalopram Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 65. Amneal Pharmaceuticals (US) Escitalopram Product Portfolio Table 66. Amneal Pharmaceuticals (US) Recent Development Table 67. Apotex (CA) Company Information Table 68. Apotex (CA) Business Overview Table 69. Apotex (CA) Escitalopram Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 70. Apotex (CA) Escitalopram Product Portfolio Table 71. Apotex (CA) Recent Development Table 72. Aurobindo Pharma (IN) Company Information Table 73. Aurobindo Pharma (IN) Business Overview Table 74. Aurobindo Pharma (IN) Escitalopram Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 75. Aurobindo Pharma (IN) Escitalopram Product Portfolio Table 76. Aurobindo Pharma (IN) Recent Development Table 77. Forest Laboratories (US) Company Information Table 78. Forest Laboratories (US) Business Overview Table 79. Forest Laboratories (US) Escitalopram Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 80. Forest Laboratories (US) Escitalopram Product Portfolio Table 81. Forest Laboratories (US) Recent Development Table 82. Hetero Drugs (IN) Company Information Table 83. Hetero Drugs (IN) Business Overview Table 84. Hetero Drugs (IN) Escitalopram Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 85. Hetero Drugs (IN) Escitalopram Product Portfolio Table 86. Hetero Drugs (IN) Recent Development Table 87. Hikma Pharmaceuticals (UK) Company Information Table 88. Hikma Pharmaceuticals (UK) Business Overview Table 89. Hikma Pharmaceuticals (UK) Escitalopram Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 90. Hikma Pharmaceuticals (UK) Escitalopram Product Portfolio Table 91. Hikma Pharmaceuticals (UK) Recent Development Table 92. Hunan Dongting Pharmaceutical (CN) Company Information Table 93. Hunan Dongting Pharmaceutical (CN) Business Overview Table 94. Hunan Dongting Pharmaceutical (CN) Escitalopram Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 95. Hunan Dongting Pharmaceutical (CN) Escitalopram Product Portfolio Table 96. Hunan Dongting Pharmaceutical (CN) Recent Development Table 97. Jewim Pharmaceutical (Shandong) Company Information Table 98. Jewim Pharmaceutical (Shandong) Business Overview Table 99. Jewim Pharmaceutical (Shandong) Escitalopram Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 100. Jewim Pharmaceutical (Shandong) Escitalopram Product Portfolio Table 101. Jewim Pharmaceutical (Shandong) Recent Development Table 102. Lundbeck (DK) Company Information Table 103. Lundbeck (DK) Business Overview Table 104. Lundbeck (DK) Escitalopram Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 105. Lundbeck (DK) Escitalopram Product Portfolio Table 106. Lundbeck (DK) Recent Development Table 107. Lupin (IN) Company Information Table 108. Lupin (IN) Business Overview Table 109. Lupin (IN) Escitalopram Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 110. Lupin (IN) Escitalopram Product Portfolio Table 111. Lupin (IN) Recent Development Table 112. Macleods Pharmaceuticals (IN) Company Information Table 113. Macleods Pharmaceuticals (IN) Business Overview Table 114. Macleods Pharmaceuticals (IN) Escitalopram Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 115. Macleods Pharmaceuticals (IN) Escitalopram Product Portfolio Table 116. Macleods Pharmaceuticals (IN) Recent Development Table 117. Silarx Pharmacueticals (US) Company Information Table 118. Silarx Pharmacueticals (US) Business Overview Table 119. Silarx Pharmacueticals (US) Escitalopram Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 120. Silarx Pharmacueticals (US) Escitalopram Product Portfolio Table 121. Silarx Pharmacueticals (US) Recent Development Table 122. TEVA (Israel) Company Information Table 123. TEVA (Israel) Business Overview Table 124. TEVA (Israel) Escitalopram Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 125. TEVA (Israel) Escitalopram Product Portfolio Table 126. TEVA (Israel) Recent Development Table 127. Xidian Pharmaceutical (CN) Company Information Table 128. Xidian Pharmaceutical (CN) Business Overview Table 129. Xidian Pharmaceutical (CN) Escitalopram Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 130. Xidian Pharmaceutical (CN) Escitalopram Product Portfolio Table 131. Xidian Pharmaceutical (CN) Recent Development Table 132. Zhejiang Conba Pharmaceutical (CN) Company Information Table 133. Zhejiang Conba Pharmaceutical (CN) Business Overview Table 134. Zhejiang Conba Pharmaceutical (CN) Escitalopram Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 135. Zhejiang Conba Pharmaceutical (CN) Escitalopram Product Portfolio Table 136. Zhejiang Conba Pharmaceutical (CN) Recent Development Table 137. Mylan (US) Company Information Table 138. Mylan (US) Business Overview Table 139. Mylan (US) Escitalopram Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 140. Mylan (US) Escitalopram Product Portfolio Table 141. Mylan (US) Recent Development Table 142. Novartis (US) Company Information Table 143. Novartis (US) Business Overview Table 144. Novartis (US) Escitalopram Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 145. Novartis (US) Escitalopram Product Portfolio Table 146. Novartis (US) Recent Development Table 147. Sichuan Kelun Pharmaceutical (CN) Company Information Table 148. Sichuan Kelun Pharmaceutical (CN) Business Overview Table 149. Sichuan Kelun Pharmaceutical (CN) Escitalopram Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 150. Sichuan Kelun Pharmaceutical (CN) Escitalopram Product Portfolio Table 151. Sichuan Kelun Pharmaceutical (CN) Recent Development Table 152. Xian Janssen Pharmaceutical (CN) Company Information Table 153. Xian Janssen Pharmaceutical (CN) Business Overview Table 154. Xian Janssen Pharmaceutical (CN) Escitalopram Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 155. Xian Janssen Pharmaceutical (CN) Escitalopram Product Portfolio Table 156. Xian Janssen Pharmaceutical (CN) Recent Development Table 157. Zhejiang Huahai Pharmaceutical (CN) Company Information Table 158. Zhejiang Huahai Pharmaceutical (CN) Business Overview Table 159. Zhejiang Huahai Pharmaceutical (CN) Escitalopram Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 160. Zhejiang Huahai Pharmaceutical (CN) Escitalopram Product Portfolio Table 161. Zhejiang Huahai Pharmaceutical (CN) Recent Development Table 162. North America Escitalopram Revenue by Type (2021-2026) & (US$ Million) Table 163. North America Escitalopram Revenue by Type (2027-2032) & (US$ Million) Table 164. North America Escitalopram Sales by Type (2021-2026) & (K Units) Table 165. North America Escitalopram Sales by Type (2027-2032) & (K Units) Table 166. North America Escitalopram Sales Price by Type (2021-2026) & (US$/Unit) Table 167. North America Escitalopram Sales Price by Type (2027-2032) & (US$/Unit) Table 168. North America Escitalopram Revenue by Application (2021-2026) & (US$ Million) Table 169. North America Escitalopram Revenue by Application (2027-2032) & (US$ Million) Table 170. North America Escitalopram Sales by Application (2021-2026) & (K Units) Table 171. North America Escitalopram Sales by Application (2027-2032) & (K Units) Table 172. North America Escitalopram Sales Price by Application (2021-2026) & (US$/Unit) Table 173. North America Escitalopram Sales Price by Application (2027-2032) & (US$/Unit) Table 174. North America Escitalopram Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 175. North America Escitalopram Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 176. North America Escitalopram Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 177. North America Escitalopram Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 178. North America Escitalopram Sales by Country (2021-2026) & (K Units) Table 179. North America Escitalopram Sales by Country (2027-2032) & (K Units) Table 180. North America Escitalopram Sales Price by Country (2021-2026) & (US$/Unit) Table 181. North America Escitalopram Sales Price by Country (2027-2032) & (US$/Unit) Table 182. United States Escitalopram Revenue (2021-2032) & (US$ Million) Table 183. Canada Escitalopram Revenue (2021-2032) & (US$ Million) Table 184. Mexico Escitalopram Revenue (2021-2032) & (US$ Million) Table 185. Europe Escitalopram Revenue by Type (2021-2026) & (US$ Million) Table 186. Europe Escitalopram Revenue by Type (2027-2032) & (US$ Million) Table 187. Europe Escitalopram Sales by Type (2021-2026) & (K Units) Table 188. Europe Escitalopram Sales by Type (2027-2032) & (K Units) Table 189. Europe Escitalopram Sales Price by Type (2021-2026) & (US$/Unit) Table 190. Europe Escitalopram Sales Price by Type (2027-2032) & (US$/Unit) Table 191. Europe Escitalopram Revenue by Application (2021-2026) & (US$ Million) Table 192. Europe Escitalopram Revenue by Application (2027-2032) & (US$ Million) Table 193. Europe Escitalopram Sales by Application (2021-2026) & (K Units) Table 194. Europe Escitalopram Sales by Application (2027-2032) & (K Units) Table 195. Europe Escitalopram Sales Price by Application (2021-2026) & (US$/Unit) Table 196. Europe Escitalopram Sales Price by Application (2027-2032) & (US$/Unit) Table 197. Europe Escitalopram Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 198. Europe Escitalopram Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 199. Europe Escitalopram Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 200. Europe Escitalopram Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 201. Europe Escitalopram Sales by Country (2021-2026) & (K Units) Table 202. Europe Escitalopram Sales by Country (2027-2032) & (K Units) Table 203. Europe Escitalopram Sales Price by Country (2021-2026) & (US$/Unit) Table 204. Europe Escitalopram Sales Price by Country (2027-2032) & (US$/Unit) Table 205. Germany Escitalopram Revenue (2021-2032) & (US$ Million) Table 206. France Escitalopram Revenue (2021-2032) & (US$ Million) Table 207. U.K. Escitalopram Revenue (2021-2032) & (US$ Million) Table 208. Italy Escitalopram Revenue (2021-2032) & (US$ Million) Table 209. Russia Escitalopram Revenue (2021-2032) & (US$ Million) Table 210. Spain Escitalopram Revenue (2021-2032) & (US$ Million) Table 211. Netherlands Escitalopram Revenue (2021-2032) & (US$ Million) Table 212. Switzerland Escitalopram Revenue (2021-2032) & (US$ Million) Table 213. Sweden Escitalopram Revenue (2021-2032) & (US$ Million) Table 214. Poland Escitalopram Revenue (2021-2032) & (US$ Million) Table 215. China Escitalopram Revenue by Type (2021-2026) & (US$ Million) Table 216. China Escitalopram Revenue by Type (2027-2032) & (US$ Million) Table 217. China Escitalopram Sales by Type (2021-2026) & (K Units) Table 218. China Escitalopram Sales by Type (2027-2032) & (K Units) Table 219. China Escitalopram Sales Price by Type (2021-2026) & (US$/Unit) Table 220. China Escitalopram Sales Price by Type (2027-2032) & (US$/Unit) Table 221. China Escitalopram Revenue by Application (2021-2026) & (US$ Million) Table 222. China Escitalopram Revenue by Application (2027-2032) & (US$ Million) Table 223. China Escitalopram Sales by Application (2021-2026) & (K Units) Table 224. China Escitalopram Sales by Application (2027-2032) & (K Units) Table 225. China Escitalopram Sales Price by Application (2021-2026) & (US$/Unit) Table 226. China Escitalopram Sales Price by Application (2027-2032) & (US$/Unit) Table 227. Asia Escitalopram Revenue by Type (2021-2026) & (US$ Million) Table 228. Asia Escitalopram Revenue by Type (2027-2032) & (US$ Million) Table 229. Asia Escitalopram Sales by Type (2021-2026) & (K Units) Table 230. Asia Escitalopram Sales by Type (2027-2032) & (K Units) Table 231. Asia Escitalopram Sales Price by Type (2021-2026) & (US$/Unit) Table 232. Asia Escitalopram Sales Price by Type (2027-2032) & (US$/Unit) Table 233. Asia Escitalopram Revenue by Application (2021-2026) & (US$ Million) Table 234. Asia Escitalopram Revenue by Application (2027-2032) & (US$ Million) Table 235. Asia Escitalopram Sales by Application (2021-2026) & (K Units) Table 236. Asia Escitalopram Sales by Application (2027-2032) & (K Units) Table 237. Asia Escitalopram Sales Price by Application (2021-2026) & (US$/Unit) Table 238. Asia Escitalopram Sales Price by Application (2027-2032) & (US$/Unit) Table 239. Asia Escitalopram Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 240. Asia Escitalopram Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 241. Asia Escitalopram Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 242. Asia Escitalopram Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 243. Asia Escitalopram Sales by Country (2021-2026) & (K Units) Table 244. Asia Escitalopram Sales by Country (2027-2032) & (K Units) Table 245. Asia Escitalopram Sales Price by Country (2021-2026) & (US$/Unit) Table 246. Asia Escitalopram Sales Price by Country (2027-2032) & (US$/Unit) Table 247. Japan Escitalopram Revenue (2021-2032) & (US$ Million) Table 248. South Korea Escitalopram Revenue (2021-2032) & (US$ Million) Table 249. India Escitalopram Revenue (2021-2032) & (US$ Million) Table 250. Australia Escitalopram Revenue (2021-2032) & (US$ Million) Table 251. Taiwan Escitalopram Revenue (2021-2032) & (US$ Million) Table 252. Southeast Asia Escitalopram Revenue (2021-2032) & (US$ Million) Table 253. SAMEA Escitalopram Revenue by Type (2021-2026) & (US$ Million) Table 254. SAMEA Escitalopram Revenue by Type (2027-2032) & (US$ Million) Table 255. SAMEA Escitalopram Sales by Type (2021-2026) & (K Units) Table 256. SAMEA Escitalopram Sales by Type (2027-2032) & (K Units) Table 257. SAMEA Escitalopram Sales Price by Type (2021-2026) & (US$/Unit) Table 258. SAMEA Escitalopram Sales Price by Type (2027-2032) & (US$/Unit) Table 259. SAMEA Escitalopram Revenue by Application (2021-2026) & (US$ Million) Table 260. SAMEA Escitalopram Revenue by Application (2027-2032) & (US$ Million) Table 261. SAMEA Escitalopram Sales by Application (2021-2026) & (K Units) Table 262. SAMEA Escitalopram Sales by Application (2027-2032) & (K Units) Table 263. SAMEA Escitalopram Sales Price by Application (2021-2026) & (US$/Unit) Table 264. SAMEA Escitalopram Sales Price by Application (2027-2032) & (US$/Unit) Table 265. SAMEA Escitalopram Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 266. SAMEA Escitalopram Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 267. SAMEA Escitalopram Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 268. SAMEA Escitalopram Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 269. SAMEA Escitalopram Sales by Country (2021-2026) & (K Units) Table 270. SAMEA Escitalopram Sales by Country (2027-2032) & (K Units) Table 271. SAMEA Escitalopram Sales Price by Country (2021-2026) & (US$/Unit) Table 272. SAMEA Escitalopram Sales Price by Country (2027-2032) & (US$/Unit) Table 273. Brazil Escitalopram Revenue (2021-2032) & (US$ Million) Table 274. Argentina Escitalopram Revenue (2021-2032) & (US$ Million) Table 275. Chile Escitalopram Revenue (2021-2032) & (US$ Million) Table 276. Colombia Escitalopram Revenue (2021-2032) & (US$ Million) Table 277. Peru Escitalopram Revenue (2021-2032) & (US$ Million) Table 278. Saudi Arabia Escitalopram Revenue (2021-2032) & (US$ Million) Table 279. Israel Escitalopram Revenue (2021-2032) & (US$ Million) Table 280. UAE Escitalopram Revenue (2021-2032) & (US$ Million) Table 281. Turkey Escitalopram Revenue (2021-2032) & (US$ Million) Table 282. Iran Escitalopram Revenue (2021-2032) & (US$ Million) Table 283. Egypt Escitalopram Revenue (2021-2032) & (US$ Million) Table 284. Key Raw Materials Table 285. Raw Materials Key Suppliers Table 286. Escitalopram Distributors List Table 287. Escitalopram Customers List Table 288. Research Programs/Design for This Report Table 289. Authors List of This Report Table 290. Secondary Sources Table 291. Primary Sources List of Figures Figure 1. Escitalopram Image Figure 2. Global Escitalopram Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Escitalopram Market Size Share 2021 VS 2025 VS 2032 Figure 4. Tablets Image Figure 5. Solution Image Figure 6. Global Escitalopram Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Escitalopram Market Size Share 2021 VS 2025 VS 2032 Figure 8. Retail Pharmacies Image Figure 9. Online Pharmacies Image Figure 10. Hospital Pharmacies Image Figure 11. Global Escitalopram Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 12. Global Escitalopram Revenue (2021-2032) & (US$ Million) Figure 13. Global Escitalopram Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 14. Global Escitalopram Revenue Market Share by Region: 2025 Versus 2032 Figure 15. Global Escitalopram Revenue Market Share by Region (2021-2032) Figure 16. Global Escitalopram Sales (2021-2032) & (K Units) Figure 17. Global Escitalopram Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 18. Global Escitalopram Sales Market Share by Region (2021-2032) Figure 19. US & Canada & Mexico Escitalopram Sales YoY (2021-2032) & (K Units) Figure 20. Europe Escitalopram Sales YoY (2021-2032) & (K Units) Figure 21. China Escitalopram Sales YoY (2021-2032) & (K Units) Figure 22. Asia (Excluding China) Escitalopram Sales YoY (2021-2032) & (K Units) Figure 23. South America, Middle East and Africa Escitalopram Sales YoY (2021-2032) & (K Units) Figure 24. Global Escitalopram Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 25. Global Escitalopram Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 26. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 27. Global Escitalopram Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 28. Global Escitalopram Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 29. Global Escitalopram Revenue Market Share by Type (2021-2032) Figure 30. Global Escitalopram Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 31. Global Escitalopram Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 32. Global Escitalopram Sales Market Share by Type (2021-2032) Figure 33. Global Escitalopram Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 34. Global Escitalopram Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 35. Global Escitalopram Revenue Market Share by Application (2021-2032) Figure 36. Global Escitalopram Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 37. Global Escitalopram Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 38. Global Escitalopram Sales Market Share by Application (2021-2032) Figure 39. North America Escitalopram Revenue Share by Type (2021-2032) Figure 40. North America Escitalopram Sales Share by Type (2021-2032) Figure 41. North America Escitalopram Revenue Share by Application (2021-2032) Figure 42. North America Escitalopram Sales Share by Application (2021-2032) Figure 43. North America Escitalopram Revenue Share by Country (2021-2032) Figure 44. North America Escitalopram Sales Share by Country (2021-2032) Figure 45. Europe Escitalopram Revenue Share by Type (2021-2032) Figure 46. Europe Escitalopram Sales Share by Type (2021-2032) Figure 47. Europe Escitalopram Revenue Share by Application (2021-2032) Figure 48. Europe Escitalopram Sales Share by Application (2021-2032) Figure 49. Europe Escitalopram Revenue Share by Country (2021-2032) Figure 50. Europe Escitalopram Sales Share by Country (2021-2032) Figure 51. China Escitalopram Revenue Share by Type (2021-2032) Figure 52. China Escitalopram Sales Share by Type (2021-2032) Figure 53. China Escitalopram Revenue Share by Application (2021-2032) Figure 54. China Escitalopram Sales Share by Application (2021-2032) Figure 55. Asia Escitalopram Revenue Share by Type (2021-2032) Figure 56. Asia Escitalopram Sales Share by Type (2021-2032) Figure 57. Asia Escitalopram Revenue Share by Application (2021-2032) Figure 58. Asia Escitalopram Sales Share by Application (2021-2032) Figure 59. Asia Escitalopram Revenue Share by Country (2021-2032) Figure 60. Asia Escitalopram Sales Share by Country (2021-2032) Figure 61. SAMEA Escitalopram Revenue Share by Type (2021-2032) Figure 62. SAMEA Escitalopram Sales Share by Type (2021-2032) Figure 63. SAMEA Escitalopram Revenue Share by Application (2021-2032) Figure 64. SAMEA Escitalopram Sales Share by Application (2021-2032) Figure 65. SAMEA Escitalopram Revenue Share by Country (2021-2032) Figure 66. SAMEA Escitalopram Sales Share by Country (2021-2032) Figure 67. Escitalopram Value Chain Figure 68. Manufacturing Cost Structure Figure 69. Escitalopram Production Mode & Process Figure 70. Direct Comparison with Distribution Share Figure 71. Distributors Profiles Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • Tablets
  • Solution
Applications
  • Retail Pharmacies
  • Online Pharmacies
  • Hospital Pharmacies
Companies covered
  • Accord Healthcare (IN)
  • Amneal Pharmaceuticals (US)
  • Apotex (CA)
  • Aurobindo Pharma (IN)
  • Forest Laboratories (US)
  • Hetero Drugs (IN)
  • Hikma Pharmaceuticals (UK)
  • Hunan Dongting Pharmaceutical (CN)
  • Jewim Pharmaceutical (Shandong)
  • Lundbeck (DK)
  • Lupin (IN)
  • Macleods Pharmaceuticals (IN)
  • Silarx Pharmacueticals (US)
  • TEVA (Israel)
  • Xidian Pharmaceutical (CN)
  • Zhejiang Conba Pharmaceutical (CN)
  • Mylan (US)
  • Novartis (US)
  • Sichuan Kelun Pharmaceutical (CN)
  • Xian Janssen Pharmaceutical (CN)
  • Zhejiang Huahai Pharmaceutical (CN)

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Escitalopram Market by Type
  3. 1.2.1 Global Escitalopram Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Tablets
  5. 1.2.3 Solution
  6. 1.3 Escitalopram Market by Application
  7. 1.3.1 Global Escitalopram Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Retail Pharmacies
  9. 1.3.3 Online Pharmacies
  10. 1.3.4 Hospital Pharmacies
  11. 1.4 Assumptions and Limitations
  12. 1.5 Study Goals and Objectives
2 Escitalopram Market Dynamics
  1. 2.1 Escitalopram Industry Trends
  2. 2.2 Escitalopram Industry Drivers
  3. 2.3 Escitalopram Industry Opportunities and Challenges
  4. 2.4 Escitalopram Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Escitalopram Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Escitalopram Revenue by Region
  3. 3.2.1 Global Escitalopram Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Escitalopram Revenue by Region (2021-2026)
  5. 3.2.3 Global Escitalopram Revenue by Region (2027-2032)
  6. 3.2.4 Global Escitalopram Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Escitalopram Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Escitalopram Sales by Region
  9. 3.4.1 Global Escitalopram Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Escitalopram Sales by Region (2021-2026)
  11. 3.4.3 Global Escitalopram Sales by Region (2027-2032)
  12. 3.4.4 Global Escitalopram Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Escitalopram Revenue by Manufacturers
  2. 4.1.1 Global Escitalopram Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Escitalopram Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Escitalopram Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Escitalopram Sales by Manufacturers
  6. 4.2.1 Global Escitalopram Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Escitalopram Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Escitalopram Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Escitalopram Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Escitalopram Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Escitalopram Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Escitalopram Manufacturers, Product Type & Application
  13. 4.7 Global Escitalopram Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Escitalopram Market CR5 and HHI
  16. 4.8.2 2025 Escitalopram Tier 1, Tier 2, and Tier 3
5 Escitalopram Market by Type
  1. 5.1 Global Escitalopram Revenue by Type
  2. 5.1.1 Global Escitalopram Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Escitalopram Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Escitalopram Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Escitalopram Sales by Type
  6. 5.2.1 Global Escitalopram Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Escitalopram Sales by Type (2021-2032) & (K Units)
  8. 5.2.3 Global Escitalopram Sales Market Share by Type (2021-2032)
  9. 5.3 Global Escitalopram Price by Type
6 Escitalopram Market by Application
  1. 6.1 Global Escitalopram Revenue by Application
  2. 6.1.1 Global Escitalopram Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Escitalopram Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Escitalopram Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Escitalopram Sales by Application
  6. 6.2.1 Global Escitalopram Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Escitalopram Sales by Application (2021-2032) & (K Units)
  8. 6.2.3 Global Escitalopram Sales Market Share by Application (2021-2032)
  9. 6.3 Global Escitalopram Price by Application
7 Company Profiles
  1. 7.1 Accord Healthcare (IN)
  2. 7.1.1 Accord Healthcare (IN) Company Information
  3. 7.1.2 Accord Healthcare (IN) Business Overview
  4. 7.1.3 Accord Healthcare (IN) Escitalopram Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Accord Healthcare (IN) Escitalopram Product Portfolio
  6. 7.1.5 Accord Healthcare (IN) Recent Developments
  7. 7.2 Amneal Pharmaceuticals (US)
  8. 7.2.1 Amneal Pharmaceuticals (US) Company Information
  9. 7.2.2 Amneal Pharmaceuticals (US) Business Overview
  10. 7.2.3 Amneal Pharmaceuticals (US) Escitalopram Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Amneal Pharmaceuticals (US) Escitalopram Product Portfolio
  12. 7.2.5 Amneal Pharmaceuticals (US) Recent Developments
  13. 7.3 Apotex (CA)
  14. 7.3.1 Apotex (CA) Company Information
  15. 7.3.2 Apotex (CA) Business Overview
  16. 7.3.3 Apotex (CA) Escitalopram Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Apotex (CA) Escitalopram Product Portfolio
  18. 7.3.5 Apotex (CA) Recent Developments
  19. 7.4 Aurobindo Pharma (IN)
  20. 7.4.1 Aurobindo Pharma (IN) Company Information
  21. 7.4.2 Aurobindo Pharma (IN) Business Overview
  22. 7.4.3 Aurobindo Pharma (IN) Escitalopram Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Aurobindo Pharma (IN) Escitalopram Product Portfolio
  24. 7.4.5 Aurobindo Pharma (IN) Recent Developments
  25. 7.5 Forest Laboratories (US)
  26. 7.5.1 Forest Laboratories (US) Company Information
  27. 7.5.2 Forest Laboratories (US) Business Overview
  28. 7.5.3 Forest Laboratories (US) Escitalopram Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Forest Laboratories (US) Escitalopram Product Portfolio
  30. 7.5.5 Forest Laboratories (US) Recent Developments
  31. 7.6 Hetero Drugs (IN)
  32. 7.6.1 Hetero Drugs (IN) Company Information
  33. 7.6.2 Hetero Drugs (IN) Business Overview
  34. 7.6.3 Hetero Drugs (IN) Escitalopram Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 Hetero Drugs (IN) Escitalopram Product Portfolio
  36. 7.6.5 Hetero Drugs (IN) Recent Developments
  37. 7.7 Hikma Pharmaceuticals (UK)
  38. 7.7.1 Hikma Pharmaceuticals (UK) Company Information
  39. 7.7.2 Hikma Pharmaceuticals (UK) Business Overview
  40. 7.7.3 Hikma Pharmaceuticals (UK) Escitalopram Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 Hikma Pharmaceuticals (UK) Escitalopram Product Portfolio
  42. 7.7.5 Hikma Pharmaceuticals (UK) Recent Developments
  43. 7.8 Hunan Dongting Pharmaceutical (CN)
  44. 7.8.1 Hunan Dongting Pharmaceutical (CN) Company Information
  45. 7.8.2 Hunan Dongting Pharmaceutical (CN) Business Overview
  46. 7.8.3 Hunan Dongting Pharmaceutical (CN) Escitalopram Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 Hunan Dongting Pharmaceutical (CN) Escitalopram Product Portfolio
  48. 7.8.5 Hunan Dongting Pharmaceutical (CN) Recent Developments
  49. 7.9 Jewim Pharmaceutical (Shandong)
  50. 7.9.1 Jewim Pharmaceutical (Shandong) Company Information
  51. 7.9.2 Jewim Pharmaceutical (Shandong) Business Overview
  52. 7.9.3 Jewim Pharmaceutical (Shandong) Escitalopram Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 Jewim Pharmaceutical (Shandong) Escitalopram Product Portfolio
  54. 7.9.5 Jewim Pharmaceutical (Shandong) Recent Developments
  55. 7.10 Lundbeck (DK)
  56. 7.10.1 Lundbeck (DK) Company Information
  57. 7.10.2 Lundbeck (DK) Business Overview
  58. 7.10.3 Lundbeck (DK) Escitalopram Sales, Revenue, Price and Gross Margin (2021-2026)
  59. 7.10.4 Lundbeck (DK) Escitalopram Product Portfolio
  60. 7.10.5 Lundbeck (DK) Recent Developments
  61. 7.11 Lupin (IN)
  62. 7.11.1 Lupin (IN) Company Information
  63. 7.11.2 Lupin (IN) Business Overview
  64. 7.11.3 Lupin (IN) Escitalopram Sales, Revenue, Price and Gross Margin (2021-2026)
  65. 7.11.4 Lupin (IN) Escitalopram Product Portfolio
  66. 7.11.5 Lupin (IN) Recent Developments
  67. 7.12 Macleods Pharmaceuticals (IN)
  68. 7.12.1 Macleods Pharmaceuticals (IN) Company Information
  69. 7.12.2 Macleods Pharmaceuticals (IN) Business Overview
  70. 7.12.3 Macleods Pharmaceuticals (IN) Escitalopram Sales, Revenue, Price and Gross Margin (2021-2026)
  71. 7.12.4 Macleods Pharmaceuticals (IN) Escitalopram Product Portfolio
  72. 7.12.5 Macleods Pharmaceuticals (IN) Recent Developments
  73. 7.13 Silarx Pharmacueticals (US)
  74. 7.13.1 Silarx Pharmacueticals (US) Company Information
  75. 7.13.2 Silarx Pharmacueticals (US) Business Overview
  76. 7.13.3 Silarx Pharmacueticals (US) Escitalopram Sales, Revenue, Price and Gross Margin (2021-2026)
  77. 7.13.4 Silarx Pharmacueticals (US) Escitalopram Product Portfolio
  78. 7.13.5 Silarx Pharmacueticals (US) Recent Developments
  79. 7.14 TEVA (Israel)
  80. 7.14.1 TEVA (Israel) Company Information
  81. 7.14.2 TEVA (Israel) Business Overview
  82. 7.14.3 TEVA (Israel) Escitalopram Sales, Revenue, Price and Gross Margin (2021-2026)
  83. 7.14.4 TEVA (Israel) Escitalopram Product Portfolio
  84. 7.14.5 TEVA (Israel) Recent Developments
  85. 7.15 Xidian Pharmaceutical (CN)
  86. 7.15.1 Xidian Pharmaceutical (CN) Company Information
  87. 7.15.2 Xidian Pharmaceutical (CN) Business Overview
  88. 7.15.3 Xidian Pharmaceutical (CN) Escitalopram Sales, Revenue, Price and Gross Margin (2021-2026)
  89. 7.15.4 Xidian Pharmaceutical (CN) Escitalopram Product Portfolio
  90. 7.15.5 Xidian Pharmaceutical (CN) Recent Developments
  91. 7.16 Zhejiang Conba Pharmaceutical (CN)
  92. 7.16.1 Zhejiang Conba Pharmaceutical (CN) Company Information
  93. 7.16.2 Zhejiang Conba Pharmaceutical (CN) Business Overview
  94. 7.16.3 Zhejiang Conba Pharmaceutical (CN) Escitalopram Sales, Revenue, Price and Gross Margin (2021-2026)
  95. 7.16.4 Zhejiang Conba Pharmaceutical (CN) Escitalopram Product Portfolio
  96. 7.16.5 Zhejiang Conba Pharmaceutical (CN) Recent Developments
  97. 7.17 Mylan (US)
  98. 7.17.1 Mylan (US) Company Information
  99. 7.17.2 Mylan (US) Business Overview
  100. 7.17.3 Mylan (US) Escitalopram Sales, Revenue, Price and Gross Margin (2021-2026)
  101. 7.17.4 Mylan (US) Escitalopram Product Portfolio
  102. 7.17.5 Mylan (US) Recent Developments
  103. 7.18 Novartis (US)
  104. 7.18.1 Novartis (US) Company Information
  105. 7.18.2 Novartis (US) Business Overview
  106. 7.18.3 Novartis (US) Escitalopram Sales, Revenue, Price and Gross Margin (2021-2026)
  107. 7.18.4 Novartis (US) Escitalopram Product Portfolio
  108. 7.18.5 Novartis (US) Recent Developments
  109. 7.19 Sichuan Kelun Pharmaceutical (CN)
  110. 7.19.1 Sichuan Kelun Pharmaceutical (CN) Company Information
  111. 7.19.2 Sichuan Kelun Pharmaceutical (CN) Business Overview
  112. 7.19.3 Sichuan Kelun Pharmaceutical (CN) Escitalopram Sales, Revenue, Price and Gross Margin (2021-2026)
  113. 7.19.4 Sichuan Kelun Pharmaceutical (CN) Escitalopram Product Portfolio
  114. 7.19.5 Sichuan Kelun Pharmaceutical (CN) Recent Developments
  115. 7.20 Xian Janssen Pharmaceutical (CN)
  116. 7.20.1 Xian Janssen Pharmaceutical (CN) Company Information
  117. 7.20.2 Xian Janssen Pharmaceutical (CN) Business Overview
  118. 7.20.3 Xian Janssen Pharmaceutical (CN) Escitalopram Sales, Revenue, Price and Gross Margin (2021-2026)
  119. 7.20.4 Xian Janssen Pharmaceutical (CN) Escitalopram Product Portfolio
  120. 7.20.5 Xian Janssen Pharmaceutical (CN) Recent Developments
  121. 7.21 Zhejiang Huahai Pharmaceutical (CN)
  122. 7.21.1 Zhejiang Huahai Pharmaceutical (CN) Company Information
  123. 7.21.2 Zhejiang Huahai Pharmaceutical (CN) Business Overview
  124. 7.21.3 Zhejiang Huahai Pharmaceutical (CN) Escitalopram Sales, Revenue, Price and Gross Margin (2021-2026)
  125. 7.21.4 Zhejiang Huahai Pharmaceutical (CN) Escitalopram Product Portfolio
  126. 7.21.5 Zhejiang Huahai Pharmaceutical (CN) Recent Developments
8 North America
  1. 8.1 North America Escitalopram Market Size by Type
  2. 8.1.1 North America Escitalopram Revenue by Type (2021-2032)
  3. 8.1.2 North America Escitalopram Sales by Type (2021-2032)
  4. 8.1.3 North America Escitalopram Price by Type (2021-2032)
  5. 8.2 North America Escitalopram Market Size by Application
  6. 8.2.1 North America Escitalopram Revenue by Application (2021-2032)
  7. 8.2.2 North America Escitalopram Sales by Application (2021-2032)
  8. 8.2.3 North America Escitalopram Price by Application (2021-2032)
  9. 8.3 North America Escitalopram Market Size by Country
  10. 8.3.1 North America Escitalopram Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Escitalopram Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Escitalopram Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
  15. 8.3.6 Mexico
9 Europe
  1. 9.1 Europe Escitalopram Market Size by Type
  2. 9.1.1 Europe Escitalopram Revenue by Type (2021-2032)
  3. 9.1.2 Europe Escitalopram Sales by Type (2021-2032)
  4. 9.1.3 Europe Escitalopram Price by Type (2021-2032)
  5. 9.2 Europe Escitalopram Market Size by Application
  6. 9.2.1 Europe Escitalopram Revenue by Application (2021-2032)
  7. 9.2.2 Europe Escitalopram Sales by Application (2021-2032)
  8. 9.2.3 Europe Escitalopram Price by Application (2021-2032)
  9. 9.3 Europe Escitalopram Market Size by Country
  10. 9.3.1 Europe Escitalopram Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Escitalopram Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Escitalopram Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Russia
  18. 9.3.9 Spain
  19. 9.3.10 Netherlands
10 China
  1. 10.1 China Escitalopram Market Size by Type
  2. 10.1.1 China Escitalopram Revenue by Type (2021-2032)
  3. 10.1.2 China Escitalopram Sales by Type (2021-2032)
  4. 10.1.3 China Escitalopram Price by Type (2021-2032)
  5. 10.2 China Escitalopram Market Size by Application
  6. 10.2.1 China Escitalopram Revenue by Application (2021-2032)
  7. 10.2.2 China Escitalopram Sales by Application (2021-2032)
  8. 10.2.3 China Escitalopram Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Escitalopram Market Size by Type
  2. 11.1.1 Asia Escitalopram Revenue by Type (2021-2032)
  3. 11.1.2 Asia Escitalopram Sales by Type (2021-2032)
  4. 11.1.3 Asia Escitalopram Price by Type (2021-2032)
  5. 11.2 Asia Escitalopram Market Size by Application
  6. 11.2.1 Asia Escitalopram Revenue by Application (2021-2032)
  7. 11.2.2 Asia Escitalopram Sales by Application (2021-2032)
  8. 11.2.3 Asia Escitalopram Price by Application (2021-2032)
  9. 11.3 Asia Escitalopram Market Size by Country
  10. 11.3.1 Asia Escitalopram Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Escitalopram Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Escitalopram Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Escitalopram Market Size by Type
  2. 12.1.1 SAMEA Escitalopram Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Escitalopram Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Escitalopram Price by Type (2021-2032)
  5. 12.2 SAMEA Escitalopram Market Size by Application
  6. 12.2.1 SAMEA Escitalopram Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Escitalopram Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Escitalopram Price by Application (2021-2032)
  9. 12.3 SAMEA Escitalopram Market Size by Country
  10. 12.3.1 SAMEA Escitalopram Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Escitalopram Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Escitalopram Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Escitalopram Value Chain Analysis
  2. 13.1.1 Escitalopram Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Escitalopram Production Mode & Process
  6. 13.2 Escitalopram Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Escitalopram Distributors
  9. 13.2.3 Escitalopram Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst